“Maintenance of Response With Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s24. https://doi.org/10.25251/skin.1.supp.23.